AstraZeneca's Pascal Soriot brought home nearly $19M last year, dwarfing some of Europe's highest pharma pay packages

Nicole DeFeudis

Editor

Amid what Pascal Soriot called an “exceptional year in terms of revenue” for AstraZeneca, the chief executive took home nearly $19 million — a slight cut …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

AstraZeneca's Pascal Soriot brought home nearly $19M last year, dwarfing some of Europe's highest pharma pay packages

Nicole DeFeudis

Editor

Sign up to read this article for free.

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lexicon ends commercial work to focus on R&D

Are programs with compounded GLP-1s safe for your population?

As­traZeneca's Pas­cal So­ri­ot brought home near­ly $19M last year, dwarf­ing some of Eu­rope's high­est phar­ma pay pack­ages

Nicole DeFeudis

Editor

Sign up to read this article for free.

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs

Lex­i­con ends com­mer­cial work to fo­cus on R&D

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

AstraZeneca's Pascal Soriot brought home nearly $19M last year, dwarfing some of Europe's highest pharma pay packages

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

Patient dies in Neurogene's Rett syndrome study

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

Lexicon ends commercial work to focus on R&D

Are programs with compounded GLP-1s safe for your population?